Costs of orphan medicinal products: longitudinal analysis of expenditure in Wales

被引：0
|
作者：
Yankier Pijeira Perez
Eifiona Wood
Dyfrig A Hughes
机构：
[1] Bangor University,Centre for Health Economics and Medicines Evaluation
来源：
Orphanet Journal of Rare Diseases | / 18卷
关键词：
Orphan Drugs; Drug costs; Costs analysis, health economics;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [41] INCENTIVISING INNOVATION OR SUPPORTING OTHER INTERESTS? EUROPEAN REGULATION OF ORPHAN MEDICINAL PRODUCTS
    Bache, Gordon
    Hervey, Tamara
    MEDICAL LAW REVIEW, 2011, 19 (01) : 123 - 131
  • [42] Public expenditure for plasma-derived and recombinant medicinal products in Italy
    Lanzoni, Monica
    Candura, Fabio
    Calizzani, Gabriele
    Biffoli, Claudia
    Grazzini, Giuliano
    BLOOD TRANSFUSION, 2013, 11 : S110 - S117
  • [43] CHALLENGES OF FUNDING ORPHAN MEDICINAL PRODUCTS IN CANADA: QUANTIFICATION OF APPROVAL RATE AND REIMBURSEMENT
    Santosuosso, M.
    Jessa-Jablonska, M.
    Ofir, M.
    O'Neill, J.
    Gibson, M.
    Hazel, M.
    Gruenbaum, Y.
    Lipschitz, Y.
    Gurfinkel, G.
    VALUE IN HEALTH, 2022, 25 (07) : S476 - S476
  • [44] Reconciling uncertainty of costs and outcomes with the need for access to orphan medicinal products: a comparative study of managed entry agreements across seven European countries
    Morel, Thomas
    Arickx, Francis
    Befrits, Gustaf
    Siviero, Paolo
    van der Meijden, Caroline
    Xoxi, Entela
    Simoens, Steven
    ORPHANET JOURNAL OF RARE DISEASES, 2013, 8
  • [45] Reconciling uncertainty of costs and outcomes with the need for access to orphan medicinal products: a comparative study of managed entry agreements across seven European countries
    Thomas Morel
    Francis Arickx
    Gustaf Befrits
    Paolo Siviero
    Caroline van der Meijden
    Entela Xoxi
    Steven Simoens
    Orphanet Journal of Rare Diseases, 8
  • [46] Managing access to advanced therapy medicinal products: Challenges for NHS Wales
    Champion, Andrew R.
    Lewis, Sian
    Davies, Stuart
    Hughes, Dyfrig A.
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2021, 87 (06) : 2444 - 2449
  • [47] The European landscape for gene therapies in orphan diseases: 6-year experience with the EMA Committee for Orphan Medicinal Products
    Palomo, Gloria M.
    Pose-Boirazian, Tomas
    Naumann-Winter, Frauke
    Costa, Enrico
    Duarte, Dinah M.
    Kalland, Maria E.
    Malikova, Eva
    Matusevicius, Darius
    Vitezic, Dinko
    Larsson, Kristina
    Magrelli, Armando
    Stoyanova-Beninska, Violeta
    Mariz, Segundo
    MOLECULAR THERAPY, 2023, 31 (12) : 3414 - 3423
  • [48] METHODOLOGICAL CHARACTERISTICS OF PIVOTAL DATA SUPPORTING ORPHAN MEDICINAL PRODUCTS AUTHORIZED BY THE EMA IN THE FIRST 15 YEARS OF THE ORPHAN REGULATION
    Fontanet, J. M.
    Vives, R.
    Pontes, C.
    Gomez, M.
    Sancho, A.
    Morros, R.
    Rios, J.
    Borras, R.
    Torres, F.
    Torrent, J.
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2016, 119 : 20 - 20
  • [49] Comparative analysis of energy expenditure and costs in neuroimaging
    Signorile, William J.
    Mahajan, Amit
    Fulbright, Robert K.
    Zubair, Adeel S.
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2024, 460
  • [50] SYSTEMATIC APPROACH TO THE DESCRIPTION OF THE EVIDENCE SUPPORTING EMA REGULATORY OPINIONS ON ORPHAN MEDICINAL PRODUCTS
    Pontes, C.
    Fontanet, M.
    Gomez-Valent, M.
    Rios, J.
    Vives, R.
    Morros, R.
    Torrent-Farnell, J.
    Torres, F.
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2014, 115 : 19 - 19
12345